

Global Companion Diagnostics for Oncology Market Insights, Forecast to 2029

<https://marketpublishers.com/r/G657BCB163BEEN.html>

Date: December 2023

Pages: 110

Price: US\$ 4,900.00 (Single User License)

ID: G657BCB163BEEN

Abstracts

This report presents an overview of global market for Companion Diagnostics for Oncology market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Companion Diagnostics for Oncology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Companion Diagnostics for Oncology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Companion Diagnostics for Oncology revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Companion Diagnostics for Oncology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Companion Diagnostics for Oncology revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Agilent Technologies, Illumina, Roche, BioMérieux, Foundation Medicine, ArcherDX, Qiagen, Thermo Fisher Scientific and Amoy Diagnostics, etc.

By Company

Agilent Technologies

Illumina

Roche

BioMérieux

Foundation Medicine

ArcherDX

Qiagen

Thermo Fisher Scientific

Amoy Diagnostics

Abbott

Segment by Type

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Segment by Application

Pharmaceutical and Biopharmaceutical Companies

Contract Research Organizations

Laboratories

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East, Africa, and Latin America

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Companion Diagnostics for Oncology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the

driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Companion Diagnostics for Oncology companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Companion Diagnostics for Oncology revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
 - 1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
 - 1.2.2 Polymerase Chain Reaction (PCR)
 - 1.2.3 Next-Generation Sequencing (NGS)
- 1.3 Market by Application
 - 1.3.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
 - 1.3.2 Pharmaceutical and Biopharmaceutical Companies
 - 1.3.3 Contract Research Organizations
 - 1.3.4 Laboratories
 - 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Companion Diagnostics for Oncology Market Perspective (2018-2029)
- 2.2 Global Companion Diagnostics for Oncology Growth Trends by Region
 - 2.2.1 Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
 - 2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029)
- 2.3 Companion Diagnostics for Oncology Market Dynamics
 - 2.3.1 Companion Diagnostics for Oncology Industry Trends
 - 2.3.2 Companion Diagnostics for Oncology Market Drivers
 - 2.3.3 Companion Diagnostics for Oncology Market Challenges
 - 2.3.4 Companion Diagnostics for Oncology Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Revenue Companion Diagnostics for Oncology by Players
 - 3.1.1 Global Companion Diagnostics for Oncology Revenue by Players (2018-2023)
 - 3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2018-2023)
- 3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Global Key Players of Companion Diagnostics for Oncology, Ranking by Revenue, 2021 VS 2022 VS 2023
- 3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
 - 3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
 - 3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2022
- 3.5 Global Key Players of Companion Diagnostics for Oncology Head office and Area Served
- 3.6 Global Key Players of Companion Diagnostics for Oncology, Product and Application
- 3.7 Global Key Players of Companion Diagnostics for Oncology, Date of Enter into This Industry
- 3.8 Mergers & Acquisitions, Expansion Plans

4 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY TYPE

- 4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
- 4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)

5 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY APPLICATION

- 5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
- 5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)

6.2 North America Companion Diagnostics for Oncology Market Size by Type

6.2.1 North America Companion Diagnostics for Oncology Market Size by Type (2018-2023)

6.2.2 North America Companion Diagnostics for Oncology Market Size by Type (2024-2029)

6.2.3 North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)

6.3 North America Companion Diagnostics for Oncology Market Size by Application

6.3.1 North America Companion Diagnostics for Oncology Market Size by Application (2018-2023)

6.3.2 North America Companion Diagnostics for Oncology Market Size by Application (2024-2029)

6.3.3 North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)

6.4 North America Companion Diagnostics for Oncology Market Size by Country

6.4.1 North America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029

6.4.2 North America Companion Diagnostics for Oncology Market Size by Country (2018-2023)

6.4.3 North America Companion Diagnostics for Oncology Market Size by Country (2024-2029)

6.4.4 United States

6.4.5 Canada

7 EUROPE

7.1 Europe Companion Diagnostics for Oncology Market Size (2018-2029)

7.2 Europe Companion Diagnostics for Oncology Market Size by Type

7.2.1 Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023)

7.2.2 Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029)

7.2.3 Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)

7.3 Europe Companion Diagnostics for Oncology Market Size by Application

7.3.1 Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023)

7.3.2 Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029)

7.3.3 Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)

7.4 Europe Companion Diagnostics for Oncology Market Size by Country

7.4.1 Europe Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029

7.4.2 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023)

7.4.3 Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 CHINA

8.1 China Companion Diagnostics for Oncology Market Size (2018-2029)

8.2 China Companion Diagnostics for Oncology Market Size by Type

8.2.1 China Companion Diagnostics for Oncology Market Size by Type (2018-2023)

8.2.2 China Companion Diagnostics for Oncology Market Size by Type (2024-2029)

8.2.3 China Companion Diagnostics for Oncology Market Share by Type (2018-2029)

8.3 China Companion Diagnostics for Oncology Market Size by Application

8.3.1 China Companion Diagnostics for Oncology Market Size by Application (2018-2023)

8.3.2 China Companion Diagnostics for Oncology Market Size by Application (2024-2029)

8.3.3 China Companion Diagnostics for Oncology Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Companion Diagnostics for Oncology Market Size (2018-2029)

9.2 Asia Companion Diagnostics for Oncology Market Size by Type

9.2.1 Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023)

9.2.2 Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029)

9.2.3 Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)

9.3 Asia Companion Diagnostics for Oncology Market Size by Application

9.3.1 Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023)

9.3.2 Asia Companion Diagnostics for Oncology Market Size by Application

(2024-2029)

9.3.3 Asia Companion Diagnostics for Oncology Market Share by Application

(2018-2029)

9.4 Asia Companion Diagnostics for Oncology Market Size by Region

9.4.1 Asia Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029

9.4.2 Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023)

9.4.3 Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

10.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type

10.2.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application

10.3.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country

10.4.1 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

11.1 Agilent Technologies

11.1.1 Agilent Technologies Company Details

11.1.2 Agilent Technologies Business Overview

11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction

11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023)

11.1.5 Agilent Technologies Recent Developments

11.2 Illumina

11.2.1 Illumina Company Details

11.2.2 Illumina Business Overview

11.2.3 Illumina Companion Diagnostics for Oncology Introduction

11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023)

11.2.5 Illumina Recent Developments

11.3 Roche

11.3.1 Roche Company Details

11.3.2 Roche Business Overview

11.3.3 Roche Companion Diagnostics for Oncology Introduction

11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023)

11.3.5 Roche Recent Developments

11.4 BioMérieux

11.4.1 BioMérieux Company Details

11.4.2 BioMérieux Business Overview

11.4.3 BioMérieux Companion Diagnostics for Oncology Introduction

11.4.4 BioMérieux Revenue in Companion Diagnostics for Oncology Business (2018-2023)

- 11.4.5 BioMérieux Recent Developments
- 11.5 Foundation Medicine
 - 11.5.1 Foundation Medicine Company Details
 - 11.5.2 Foundation Medicine Business Overview
 - 11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
 - 11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023)
 - 11.5.5 Foundation Medicine Recent Developments
- 11.6 ArcherDX
 - 11.6.1 ArcherDX Company Details
 - 11.6.2 ArcherDX Business Overview
 - 11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
 - 11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023)
 - 11.6.5 ArcherDX Recent Developments
- 11.7 Qiagen
 - 11.7.1 Qiagen Company Details
 - 11.7.2 Qiagen Business Overview
 - 11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
 - 11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023)
 - 11.7.5 Qiagen Recent Developments
- 11.8 Thermo Fisher Scientific
 - 11.8.1 Thermo Fisher Scientific Company Details
 - 11.8.2 Thermo Fisher Scientific Business Overview
 - 11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
 - 11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023)
 - 11.8.5 Thermo Fisher Scientific Recent Developments
- 11.9 Amoy Diagnostics
 - 11.9.1 Amoy Diagnostics Company Details
 - 11.9.2 Amoy Diagnostics Business Overview
 - 11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
 - 11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023)
 - 11.9.5 Amoy Diagnostics Recent Developments
- 11.10 Abbott
 - 11.10.1 Abbott Company Details
 - 11.10.2 Abbott Business Overview

- 11.10.3 Abbott Companion Diagnostics for Oncology Introduction
- 11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business
(2018-2023)
- 11.10.5 Abbott Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of Polymerase Chain Reaction (PCR)

Table 3. Key Players of Next-Generation Sequencing (NGS)

Table 4. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application (US\$ Million), 2018 VS 2022 VS 2029

Table 5. Global Companion Diagnostics for Oncology Market Size Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2018-2023)

Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2024-2029)

Table 10. Companion Diagnostics for Oncology Market Trends

Table 11. Companion Diagnostics for Oncology Market Drivers

Table 12. Companion Diagnostics for Oncology Market Challenges

Table 13. Companion Diagnostics for Oncology Market Restraints

Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Companion Diagnostics for Oncology Revenue Share by Players (2018-2023)

Table 16. Global Top Companion Diagnostics for Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)

Table 17. Global Companion Diagnostics for Oncology Industry Ranking 2021 VS 2022 VS 2023

Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2018-2023)

Table 19. Global Key Players of Companion Diagnostics for Oncology, Headquarters and Area Served

Table 20. Global Key Players of Companion Diagnostics for Oncology, Product and Application

Table 21. Global Key Players of Companion Diagnostics for Oncology, Product and Application

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2018-2023)

Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2024-2029)

Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Companion Diagnostics for Oncology Revenue Share by Application (2018-2023)

Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Companion Diagnostics for Oncology Revenue Share by Application (2024-2029)

Table 31. North America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 32. North America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US\$ Million)

Table 33. North America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 34. North America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US\$ Million)

Table 35. North America Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 36. North America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US\$ Million)

Table 37. North America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US\$ Million)

Table 38. Europe Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 39. Europe Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US\$ Million)

Table 40. Europe Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 41. Europe Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US\$ Million)

Table 42. Europe Companion Diagnostics for Oncology Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 43. Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US\$ Million)

Table 45. China Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 46. China Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US\$ Million)

Table 47. China Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 48. China Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US\$ Million)

Table 49. Asia Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 50. Asia Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US\$ Million)

Table 51. Asia Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 52. Asia Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US\$ Million)

Table 53. Asia Companion Diagnostics for Oncology Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 54. Asia Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US\$ Million)

Table 55. Asia Companion Diagnostics for Oncology Market Size by Region (2024-2029) & (US\$ Million)

Table 56. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US\$ Million)

Table 57. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Type (2024-2029) & (US\$ Million)

Table 58. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US\$ Million)

Table 59. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Application (2024-2029) & (US\$ Million)

Table 60. Middle East, Africa, and Latin America Companion Diagnostics for Oncology

Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 61. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US\$ Million)

Table 62. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US\$ Million)

Table 63. Agilent Technologies Company Details

Table 64. Agilent Technologies Business Overview

Table 65. Agilent Technologies Companion Diagnostics for Oncology Product

Table 66. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US\$ Million)

Table 67. Agilent Technologies Recent Developments

Table 68. Illumina Company Details

Table 69. Illumina Business Overview

Table 70. Illumina Companion Diagnostics for Oncology Product

Table 71. Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US\$ Million)

Table 72. Illumina Recent Developments

Table 73. Roche Company Details

Table 74. Roche Business Overview

Table 75. Roche Companion Diagnostics for Oncology Product

Table 76. Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US\$ Million)

Table 77. Roche Recent Developments

Table 78. BioMérieux Company Details

Table 79. BioMérieux Business Overview

Table 80. BioMérieux Companion Diagnostics for Oncology Product

Table 81. BioMérieux Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US\$ Million)

Table 82. BioMérieux Recent Developments

Table 83. Foundation Medicine Company Details

Table 84. Foundation Medicine Business Overview

Table 85. Foundation Medicine Companion Diagnostics for Oncology Product

Table 86. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US\$ Million)

Table 87. Foundation Medicine Recent Developments

Table 88. ArcherDX Company Details

Table 89. ArcherDX Business Overview

Table 90. ArcherDX Companion Diagnostics for Oncology Product

Table 91. ArcherDX Revenue in Companion Diagnostics for Oncology Business

(2018-2023) & (US\$ Million)

Table 92. ArcherDX Recent Developments

Table 93. Qiagen Company Details

Table 94. Qiagen Business Overview

Table 95. Qiagen Companion Diagnostics for Oncology Product

Table 96. Qiagen Revenue in Companion Diagnostics for Oncology Business

(2018-2023) & (US\$ Million)

Table 97. Qiagen Recent Developments

Table 98. Thermo Fisher Scientific Company Details

Table 99. Thermo Fisher Scientific Business Overview

Table 100. Thermo Fisher Scientific Companion Diagnostics for Oncology Product

Table 101. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology

Business (2018-2023) & (US\$ Million)

Table 102. Thermo Fisher Scientific Recent Developments

Table 103. Amoy Diagnostics Company Details

Table 104. Amoy Diagnostics Business Overview

Table 105. Amoy Diagnostics Companion Diagnostics for Oncology Product

Table 106. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology

Business (2018-2023) & (US\$ Million)

Table 107. Amoy Diagnostics Recent Developments

Table 108. Abbott Company Details

Table 109. Abbott Business Overview

Table 110. Abbott Companion Diagnostics for Oncology Product

Table 111. Abbott Revenue in Companion Diagnostics for Oncology Business

(2018-2023) & (US\$ Million)

Table 112. Abbott Recent Developments

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2022 VS 2029

Figure 3. Polymerase Chain Reaction (PCR) Features

Figure 4. Next-Generation Sequencing (NGS) Features

Figure 5. Global Companion Diagnostics for Oncology Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2022 VS 2029

Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies

Figure 8. Contract Research Organizations Case Studies

Figure 9. Laboratories Case Studies

Figure 10. Others Case Studies

Figure 11. Companion Diagnostics for Oncology Report Years Considered

Figure 12. Global Companion Diagnostics for Oncology Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 13. Global Companion Diagnostics for Oncology Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2022 VS 2029

Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2022

Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)

Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2022

Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. North America Companion Diagnostics for Oncology Market Share by Type (2018-2029)

Figure 20. North America Companion Diagnostics for Oncology Market Share by Application (2018-2029)

Figure 21. North America Companion Diagnostics for Oncology Market Share by

Country (2018-2029)

Figure 22. United States Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US\$ Million)

Figure 25. Europe Companion Diagnostics for Oncology Market Share by Type (2018-2029)

Figure 26. Europe Companion Diagnostics for Oncology Market Share by Application (2018-2029)

Figure 27. Europe Companion Diagnostics for Oncology Market Share by Country (2018-2029)

Figure 28. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. France Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. China Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US\$ Million)

Figure 35. China Companion Diagnostics for Oncology Market Share by Type (2018-2029)

Figure 36. China Companion Diagnostics for Oncology Market Share by Application (2018-2029)

Figure 37. Asia Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US\$ Million)

Figure 38. Asia Companion Diagnostics for Oncology Market Share by Type (2018-2029)

Figure 39. Asia Companion Diagnostics for Oncology Market Share by Application (2018-2029)

Figure 40. Asia Companion Diagnostics for Oncology Market Share by Region (2018-2029)

Figure 41. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. China Taiwan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. India Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Size YoY (2018-2029) & (US\$ Million)

Figure 48. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Type (2018-2029)

Figure 49. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Application (2018-2029)

Figure 50. Middle East, Africa, and Latin America Companion Diagnostics for Oncology Market Share by Country (2018-2029)

Figure 51. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 52. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 53. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 54. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 55. Israel Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 56. GCC Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 57. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 58. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 59. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 60. BioMérieux Revenue Growth Rate in Companion Diagnostics for Oncology

Business (2018-2023)

Figure 61. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 62. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 63. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 65. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 66. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

I would like to order

Product name: Global Companion Diagnostics for Oncology Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/G657BCB163BEEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G657BCB163BEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970